This Thanksgiving, families will discuss of end-of-life care wishes; FDA provides new guidance for development of abuse-deterrent opioids; Missouri reverses its restrictive policy in Medicaid for hepatitic C medicine.
With the family all together at Thanksgiving, more and more people are using the holiday dinner to discuss their wishes for end-of-life care. Kaiser Health News reported that Thanksgiving and Christmas are the 2 times of year when requests for documents that guide end-of-life care decisions surge. About one-third of US adults have written advance directives, and having this document and other advance care planning in place can increase the chance that a person’s wishes are followed at the end of their life.
The FDA is encouraging drug companies to develop generic versions of abuse-deterrent opioids that are already approved. Although there are 10 opioids with abuse-deterrent formulations on the market, uptake has been slow, and price is one significant barrier, reported MedPage Today. Generic versions of these drugs will help bring the price down. FDA also recommended studies companies can conduct to demonstrate a generic drug is at least as abuse-deterrent as the brand-name counterpart.
The high cost of hepatitis C virus drugs and the large population that needed to be treated caused some states to adopt restrictive Medicaid policies on who could receive the medication. Now, Missouri has reversed course on its policy after a lawsuit argued some Medicaid patients who needed the treatment were denied, according to the St. Louis Post-Dispatch. Court documents estimated that 13,000 Medicaid beneficiaries in Missouri have hepatitis C. While the cost of the drug was initially $93,000 for a 12-week course, the price has since come down, and an attorney for the plaintiffs argue that reversing the policy will actually save the state money in the long run.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More